| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038655800 |
| P356 | DOI | 10.1007/S40265-016-0546-7 |
| P8608 | Fatcat ID | release_xxgb3dklgzecxj63hecfpppt2a |
| P932 | PMC publication ID | 5578711 |
| P698 | PubMed publication ID | 26915027 |
| P5875 | ResearchGate publication ID | 295868156 |
| P50 | author | Irini Sereti | Q37383379 |
| P2093 | author name string | Denise C Hsu | |
| P2860 | cites work | CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract | Q22242965 |
| Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection | Q22251080 | ||
| Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells | Q24523640 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | Q24645391 | ||
| Innate immune recognition of HIV-1 | Q27025598 | ||
| Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21 | Q27334401 | ||
| CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus | Q27486398 | ||
| The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis | Q27489415 | ||
| High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin trea | Q27490328 | ||
| IL-17 and Th17 Cells | Q27860566 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| General issues on microbial translocation in HIV-infected patients | Q28081220 | ||
| Cholesterol, inflammation and innate immunity | Q28086912 | ||
| Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis | Q28141430 | ||
| Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells | Q28215003 | ||
| Type I interferons in infectious disease | Q28255842 | ||
| Rifaximin treatment in hepatic encephalopathy | Q28277660 | ||
| Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 | ||
| The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial | Q28475076 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial | Q28484460 | ||
| Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction | Q28533379 | ||
| Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected | Q28741704 | ||
| Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review | Q28755180 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| The growing burden of tuberculosis: global trends and interactions with the HIV epidemic | Q29616520 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q29620108 | ||
| HIV and Tuberculosis: a Deadly Human Syndemic | Q30052157 | ||
| Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials | Q30884055 | ||
| Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. | Q31000488 | ||
| Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study | Q31146395 | ||
| The anti-HIV-1 activity of chloroquine | Q31884593 | ||
| HIV induces TRAIL sensitivity in hepatocytes | Q33413051 | ||
| HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. | Q33513977 | ||
| Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation | Q33553358 | ||
| Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression | Q33585762 | ||
| Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation | Q33597485 | ||
| Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers | Q33713347 | ||
| Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy | Q33745859 | ||
| Interleukin-2 therapy in patients with HIV infection | Q33847543 | ||
| Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases | Q33852885 | ||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | Q33857515 | ||
| Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication | Q33872468 | ||
| Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism | Q33889154 | ||
| Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection | Q33907642 | ||
| Metabolic syndrome, C-reactive protein, and mortality in U.S. Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study | Q33960247 | ||
| Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients | Q33963850 | ||
| IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation | Q33977594 | ||
| A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals | Q34009093 | ||
| Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. | Q34126302 | ||
| Mucosal immunity in human and simian immunodeficiency lentivirus infections | Q34131265 | ||
| T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy | Q34193786 | ||
| Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort | Q34204026 | ||
| Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy | Q34206123 | ||
| X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4 | Q34221539 | ||
| Physiology. COX-2 inhibitors and cardiovascular risk | Q34281737 | ||
| Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection | Q34315572 | ||
| Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection | Q34322219 | ||
| Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy | Q34384143 | ||
| Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection | Q34430215 | ||
| Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial | Q34451794 | ||
| Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression | Q35823171 | ||
| A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States | Q35870443 | ||
| Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus | Q35894298 | ||
| The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals | Q35965167 | ||
| Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients | Q35983529 | ||
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study | Q36053935 | ||
| Rifaximin: in vitro and in vivo antibacterial activity--a review | Q36108484 | ||
| Current perspectives on HIV-associated lipodystrophy syndrome | Q36132967 | ||
| Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals | Q36230977 | ||
| Anti-inflammatory effects of statins: clinical evidence and basic mechanisms | Q36337932 | ||
| Epidemiology of viral hepatitis and HIV co-infection | Q36341016 | ||
| A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. | Q36379230 | ||
| HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation | Q36383621 | ||
| Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis | Q36452414 | ||
| Microbial translocation in the pathogenesis of HIV infection and AIDS. | Q36558287 | ||
| Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection | Q36607248 | ||
| Accelerated immune senescence and HIV-1 infection | Q36738887 | ||
| Prebiotics: the concept revisited | Q36740886 | ||
| CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection | Q36745251 | ||
| Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial | Q36765204 | ||
| Lubiprostone: a chloride channel activator for treatment of chronic constipation | Q36829143 | ||
| Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections | Q36915902 | ||
| The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial | Q36938539 | ||
| Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. | Q36967076 | ||
| HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells | Q37000907 | ||
| A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy | Q37070314 | ||
| Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study | Q37130166 | ||
| Immune effector mechanisms implicated in atherosclerosis: from mice to humans | Q37150605 | ||
| The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia | Q37193194 | ||
| Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection | Q37202576 | ||
| Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial | Q37213057 | ||
| IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection | Q37262403 | ||
| Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. | Q37294964 | ||
| Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection | Q34485916 | ||
| Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis | Q34507164 | ||
| Prostaglandins as modulators of immunity | Q34543566 | ||
| Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. | Q34601557 | ||
| The multifaceted role of pirfenidone and its novel targets. | Q34623073 | ||
| Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections | Q34627187 | ||
| The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement | Q34660076 | ||
| Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus–infected lipoatrophic men treated with pioglitazone: a pilot study | Q34672147 | ||
| Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients | Q34673075 | ||
| A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response | Q34743336 | ||
| Plasma levels of soluble CD14 independently predict mortality in HIV infection | Q34764002 | ||
| T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women | Q34764361 | ||
| The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial | Q34818798 | ||
| Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation | Q35021902 | ||
| Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms | Q35024882 | ||
| The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation | Q35030011 | ||
| Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. | Q35055172 | ||
| The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection | Q35072020 | ||
| An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses | Q35077490 | ||
| Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy | Q35102167 | ||
| Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. | Q35102590 | ||
| Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy | Q35102598 | ||
| The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. | Q35166131 | ||
| Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies | Q35169664 | ||
| Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial | Q35171253 | ||
| The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C | Q35174850 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis | Q35197266 | ||
| Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy | Q35532868 | ||
| Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. | Q35655728 | ||
| Soluble CD14 is a nonspecific marker of monocyte activation | Q35676127 | ||
| Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort | Q35705439 | ||
| Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial | Q35712284 | ||
| Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence | Q35720116 | ||
| Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV | Q35766808 | ||
| Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection | Q37309633 | ||
| HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation | Q37310421 | ||
| Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection | Q37319195 | ||
| Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. | Q37338133 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| PPARγ signaling and metabolism: the good, the bad and the future | Q37407887 | ||
| Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy | Q37505250 | ||
| Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy | Q37528422 | ||
| Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm | Q37576442 | ||
| A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects | Q37595511 | ||
| Hepatic inflammation and progressive liver fibrosis in chronic liver disease | Q37629675 | ||
| Hepatic fibrosis and the renin-angiotensin system | Q37763825 | ||
| Pathogenesis of liver fibrosis | Q37809079 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Conventional medical management of inflammatory bowel disease | Q37870434 | ||
| Atherosclerosis: current pathogenesis and therapeutic options | Q37953777 | ||
| Immunosenescence and HIV. | Q38015598 | ||
| Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. | Q38133959 | ||
| Metabolic disease in HIV infection | Q38155277 | ||
| Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals | Q38166161 | ||
| HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment | Q38357279 | ||
| Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. | Q38476717 | ||
| Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial | Q38484316 | ||
| Innate immunity against HIV-1 infection | Q38491184 | ||
| Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). | Q39470173 | ||
| Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo | Q39588498 | ||
| Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events | Q40166868 | ||
| Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy | Q40331192 | ||
| Tissue factor: molecular recognition and cofactor function. | Q40447432 | ||
| CD14 is an acute-phase protein | Q40575802 | ||
| Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study | Q41497390 | ||
| Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy | Q41921243 | ||
| Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. | Q41927429 | ||
| Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery | Q41928271 | ||
| Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders | Q41932770 | ||
| Associations between immune depression and cardiovascular events in HIV infection | Q42255667 | ||
| Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy | Q42270440 | ||
| Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. | Q42278643 | ||
| Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study | Q42282082 | ||
| Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin | Q45728845 | ||
| Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. | Q46200764 | ||
| Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort | Q46753948 | ||
| ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhoea | Q46948549 | ||
| European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted | Q48527068 | ||
| The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. | Q50937169 | ||
| Premature age-related comorbidities among HIV-infected persons compared with the general population. | Q51000618 | ||
| Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. | Q51388029 | ||
| Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. | Q51509450 | ||
| Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. | Q51859231 | ||
| CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. | Q51873827 | ||
| Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. | Q51993308 | ||
| Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. | Q52993523 | ||
| Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. | Q53608173 | ||
| Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. | Q53941835 | ||
| Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. | Q54026923 | ||
| Clinical relevance of cytomegalovirus viraemia(*,†). | Q54391854 | ||
Residual viraemia in HIV-1-infected patients with plasma viral load | Q54504612 | | ||
| High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors | Q56837773 | ||
| Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study | Q56837790 | ||
| Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis | Q57125261 | ||
| A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy | Q57181107 | ||
| Projected life expectancy of people with HIV according to timing of diagnosis | Q57476832 | ||
| Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment | Q58123225 | ||
| Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial | Q58290838 | ||
| Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration | Q59732151 | ||
| Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers | Q61415686 | ||
| Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy Is Still Higher Than in Non-HIV-Infected Individuals | Q63364000 | ||
| A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea | Q70610258 | ||
| Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden | Q72191747 | ||
| Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly | Q73127365 | ||
| Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis | Q73881440 | ||
| Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy | Q74165679 | ||
| T-cell-mediated lysis of endothelial cells in acute coronary syndromes | Q77595337 | ||
| Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly | Q77769291 | ||
| C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study | Q79370345 | ||
| Probiotics: definition, sources, selection, and uses | Q80463721 | ||
| Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients | Q81543046 | ||
| Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy | Q83128900 | ||
| Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load | Q83917425 | ||
| Medicine. Hepatitis C can be cured globally, but at what cost? | Q87383411 | ||
| Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis | Q42623275 | ||
| Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study | Q42625324 | ||
| The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy | Q42638025 | ||
| Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy | Q42720721 | ||
| Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment | Q42924252 | ||
| Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. | Q42970792 | ||
| Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia | Q43112837 | ||
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. | Q43130032 | ||
| Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials | Q43194317 | ||
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | Q43451461 | ||
| Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study | Q43552952 | ||
| Placebo-controlled trial of prednisone in advanced HIV-1 infection | Q43556071 | ||
| Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy | Q43564797 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Prevalence and predictive value of intermittent viremia with combination hiv therapy | Q43670221 | ||
| Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum | Q43686516 | ||
| Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. | Q44015315 | ||
| High prevalence of osteonecrosis of the femoral head in HIV-infected adults. | Q44047072 | ||
| A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). | Q44355646 | ||
| Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study | Q44486385 | ||
| Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population | Q44510170 | ||
| Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone | Q44868329 | ||
| Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. | Q45333318 | ||
| Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. | Q45357510 | ||
| Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus | Q45383108 | ||
| Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection | Q45420228 | ||
| Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy | Q45710801 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 533-549 | |
| P577 | publication date | 2016-02-25 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection | |
| P478 | volume | 76 |
| Q90683081 | CMV seropositivity is associated with increased microbial translocation in people living with HIV and uninfected controls |
| Q64100143 | Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol |
| Q92360248 | Evidence for Persistent Monocyte and Immune Dysregulation After Prolonged Viral Suppression Despite Normalization of Monocyte Subsets, sCD14 and sCD163 in HIV-Infected Individuals |
| Q59792830 | High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy |
| Q98237886 | Immunometabolism and HIV-1 pathogenesis: food for thought |
| Q47562735 | Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens |
| Q90194896 | Metformin effect on gut microbiota: insights for HIV-related inflammation |
| Q92188890 | Monocyte Based Correlates of Immune Activation and Viremia in HIV-Infected Long-Term Non-Progressors |
| Q54269208 | Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques. |
| Q99609907 | Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota |
| Q93010915 | Specific Activation In Vivo of HIV-1 by a Bromodomain Inhibitor from Monocytic Cells in Humanized Mice under Antiretroviral Therapy |
| Q93197905 | The Bacterium Akkermansia muciniphila: A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation |
| Q38984137 | The gut microbiome and HIV-1 pathogenesis: a two-way street |
Search more.